^
Association details:
Biomarker:LDH elevation
Cancer:Burkitt Lymphoma
Regimen:ViPOR (Gazyva (obinutuzumab) + Imbruvica (ibrutinib) + lenalidomide + + Venclexta (venetoclax))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

598 Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Published date:
11/04/2020
Excerpt:
53 pts were enrolled and treated; 17 in dose-escalation and 36 in dose-expansion. NHL subtypes included DLBCL (23), FL (19), HGBCL “double-hit” (9), and MZL (2). Of 32 aggressive pts, 34% transformed from indolent NHL. Median age was 57y (range 29-83) with stage III/IV disease in 89%, elevated LDH in 68%, and >2 EN sites in 57%.
Secondary therapy:
prednisone